Skip to main content
Equibles
PRME logo

PRME · Prime Medicine, Inc.

Track PRME — free

Use PRME with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.70 -0.01 (-0.27%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, we concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$671.09M
Shares
181.38M

PRME metrics

58 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.70
Market cap
$671.09M

Price action

19 metrics
Price change (1W)
+2.5%
Price change (30D)
+20.1%
Price change (3M)
+20.9%
Price change (6M)
-7.7%
Price change (YTD)
+6.6%
Price change (1Y)
+8.8%
Trailing year
Price change (5Y)
—
52-week high
$6.67
52-week low
$2.70
Change from 52-week high
-44.5%
Change from 52-week low
+37.0%
Annualized volatility
89.4%
Beta
2.2
RSI (14D)
59.4
Price vs SMA 50
+9.2%
Price vs SMA 200
+4.4%
Avg volume (3M)
3.23M
Relative volume
0.5
Average dollar volume
$11.03M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
181.38M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
144.9×
reciprocal yield 0.7%
P / book
16.9
reciprocal yield 5.9%
FCF yield
-23.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-28.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-12

Profitability

9 metrics
Gross margin
—
Operating margin
-4,498.1%
Trailing 12 months
Net margin
-4,342.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$196.52M
Net income (TTM)
−$187.89M
Trailing 12 months
Diluted EPS (TTM)
$-1.06
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-4.82

Growth

11 metrics
Revenue growth YoY
-61.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.63M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+37.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
-2.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-472.0%
Return on assets
-75.4%
Debt / equity
—
Current ratio
3.1
EBITDA (TTM)
−$189.12M
Free cash flow (TTM)
−$156.85M
Quick ratio
3.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$47.45M
Latest balance sheet
Cash & equivalents
$47.45M
Total assets
$249.04M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$156.05M
Capital expenditures (TTM)
$797,000
R&D (TTM)
$146.20M
SG&A (TTM)
—
Stock compensation (TTM)
$26.77M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
189
13F filer change QoQ
-4
Institutional ownership
59.4%

Short interest

3 metrics
Short interest
19.3%
Latest settlement · 13.8 days to cover
Days to cover
13.8d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1894562 CUSIP 74168J101 13F (30d) 125 filings 125 filers Visit website Investor relations